Actively Recruiting
Alpha Radiation Emitters Device for the Treatment of Recurrent Lung Cancer
Led by Alpha Tau Medical LTD. · Updated on 2025-12-02
10
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .
CONDITIONS
Official Title
Alpha Radiation Emitters Device for the Treatment of Recurrent Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically and/or cytologically proven recurrent mediastinal tumors
- Target lesion amenable for at least 50% coverage by Alpha DaRT seeds
- Up to two treatable lesions
- Interstitial radiation indication approved by multidisciplinary team
- Measurable lesion per RECIST v1.1 criteria
- Lesion size 64 3 cm in longest diameter
- Age 18 years or older
- ECOG Performance Status Scale 64 3
- Life expectancy more than 6 months
- White blood cell count 65 3500/�b5l, granulocyte 65 1500/�b5l
- Platelet count 60,000/�b5l
- Creatinine clearance 60 cc/min or 65 40 cc/min with stable creatinine levels over past 3 weeks
- AST and ALT 64 2.5 times upper limit of normal
- INR less than 1.4 for patients not on Warfarin
- Willing and able to sign informed consent
- Women of childbearing potential must have negative pregnancy test before Ra-224 implantation and use contraception for 3 months after treatment
You will not qualify if you...
- Receiving chemotherapy or immunotherapy currently
- Brain metastases or connective tissue diseases such as scleroderma or lupus
- Known allergy to any treatment components
- Undergoing systemic immunosuppressive therapy except short corticosteroids use
- Clinically significant cardiovascular disease including severe heart failure, uncontrolled coronary disease, cardiomyopathy, arrhythmia, uncontrolled hypertension, or recent myocardial infarction within 12 months
- Uncontrolled infections, psychiatric or substance abuse disorders interfering with study participation
- Additional progressing malignancy needing active treatment, except certain skin or cervical cancers
- Requires treatments not specified in this protocol that could interfere with study outcomes
- Unwilling or unable to use adequate contraception before, during, and 3 months after study
- Participation in another interventional study within past 30 days that conflicts with this study
- High risk of not following the study protocol
- Breastfeeding or women of childbearing potential unwilling to use contraception for 3 months post-treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hadassah University Hospital
Jerusalem, Israel, 9777605
Actively Recruiting
Research Team
L
Liron Dimnik
CONTACT
A
Aviya Hoida
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here